Clinical Trials · global
More evidence for fully subcutaneous treatment of Crohn’s disease: Phase 3 Skyrizi trial reports endoscopic remission results
Subcutaneous administration for both induction and maintenance treatment could allow more flexible treatment scheduling. New AFFIRM data show that patients who had achieved a clinical response during induction had a higher rate of endoscopic remission at Week 24 than those receiving placebo; this administration approach remains under review by US and European regulators.
For patients with Crohn’s disease, treatment needs to relieve abdominal pain and diarrhea while also controlling persistent inflammation in the gut. Subcutaneous administration from the start of treatment through maintenance could allow more flexible treatment scheduling. On October 13, AbbVie announced new results from the Phase 3 AFFIRM trial of Skyrizi (risankizumab), providing further evidence for this treatment approach.
The data presented at the American College of Gastroenterology (ACG) annual meeting focused on intestinal improvement at Week 24. Among patients who had achieved a clinical response during induction and subsequently entered maintenance, 35.8% in the subcutaneous risankizumab group achieved endoscopic remission, compared with 9.1% in the placebo group. This measure is determined using intestinal lesion scores and reflects a reduction in visible inflammation, assessing a different aspect of treatment outcomes from whether patients’ symptoms have resolved.
AFFIRM enrolled 289 adults with moderately to severely active Crohn’s disease, randomly assigning them in a 2:1 ratio to receive subcutaneous treatment or placebo; 65% had previously had an inadequate response to at least one advanced therapy. In its October 11 preview of the annual meeting, AbbVie had already reported that both co-primary endpoints—clinical remission and endoscopic response at Week 12—were significantly better than placebo. The later results announced this time add information about intestinal changes after induction treatment.
Outcomes also differed among patients with different treatment histories. According to data released by AbbVie and compiled by AllSci, the Week 24 endoscopic remission rate in the subgroup with no previous advanced therapy failure was 45.1%, compared with 6.7% for placebo; among those who had had an inadequate response to advanced therapy, the rates were 30.1% and 10.3%, respectively. The treatment groups had higher rates in both subgroups, but these figures alone cannot establish which type of patient will necessarily benefit more.
The most important consideration when interpreting the results is the population analyzed. The Week 24 data cover only patients who had achieved a clinical response during induction, rather than all patients initially randomized, so 35.8% cannot be interpreted as the probability of remission for everyone starting treatment. AllSci also noted that these results did not include p-values or confidence intervals. AbbVie’s annual meeting preview described the Week 24 difference as numerically higher, which is insufficient to claim statistically significant superiority over placebo.
Risankizumab binds to the p19 subunit of interleukin-23 (IL-23), blocking this signaling pathway involved in inflammation. AbbVie said the safety profile through Week 24 was consistent with the drug’s established profile, with no new safety signals identified. However, this announcement did not provide detailed adverse event rates, and short-term results cannot replace longer-term safety follow-up.
Skyrizi is already approved for adults with Crohn’s disease, and the current applications focus on adding a subcutaneous induction regimen. These applications remain under review by the US Food and Drug Administration and the European Medicines Agency. If approved, fully subcutaneous treatment would provide another administration option. Whether it can reduce patients’ treatment burden, and how long the benefits can be sustained, will require further data.